Mutated genes in this cancer type: {'KEAP1', 'STK11', 'FLT3', 'SMARCA4', 'CBL', 'ZFHX3', 'ATR', 'KRAS'}

Comparing recall of recovering targets of approved drugs not in training set vs random
K: [1, 10, 20, 30, 50, 100, 200, 300, 400, 500, 1000]
Recall (Approved): [0.0, 0.0426, 0.1064, 0.1064, 0.2128, 0.2553, 0.3191, 0.3404, 0.3404, 0.3404, 0.4468]
Recall (Random): [0.0, 0.0, 0.0, 0.0, 0.0, 0.0213, 0.0426, 0.0638, 0.0638, 0.0638, 0.1064]

Comparing recall of recovering targets of approved drugs not in training set vs random (additionally, only considering the targets that are not in the training set!)
K: [1, 10, 20, 30, 50, 100, 200, 300, 400, 500, 1000]
Recall (Approved): [0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.1053]
Recall (Random): [0.0, 0.0, 0.0, 0.0, 0.0, 0.0526, 0.1053, 0.1053, 0.1053, 0.1053, 0.1579]

Comparing recall of recovering targets perturbed in the dataset which are not targets of approved drugs in training set vs random
K: [1, 10, 20, 30, 50, 100, 200, 300, 400, 500, 1000]
Recall (Perturbed not approved): [0.0012, 0.0098, 0.0185, 0.0308, 0.0467, 0.0861, 0.1402, 0.1833, 0.2116, 0.2485, 0.3678]
Recall (Random): [0.0, 0.0, 0.0012, 0.0025, 0.0062, 0.0111, 0.0209, 0.032, 0.0418, 0.0467, 0.0923]


USE CASES:
Of the top 10 predicted genes, these ones are targets of approved drugs not in the training set: ['KDR', 'FLT3']
The approved drugs (not in training) that have at least one of those genes as targets are: {'pralsetinib': ['RET', 'DDR1', 'NTRK3', 'FLT3', 'JAK1', 'JAK2', 'NTRK1', 'KDR', 'PDGFRB', 'FGFR1', 'FGFR2'], 'brigatinib': ['ALK', 'EGFR', 'ABL1', 'IGF1R', 'FLT3', 'INSR', 'MET', 'ERBB4', 'ERBB2'], 'ramucirumab': ['KDR']}
--

USE CASES:
Of the top 20 predicted genes, these ones are targets of approved drugs not in the training set: ['KDR', 'RET', 'FLT3', 'EGFR', 'PDGFRB']
The approved drugs (not in training) that have at least one of those genes as targets are: {'pralsetinib': ['RET', 'DDR1', 'NTRK3', 'FLT3', 'JAK1', 'JAK2', 'NTRK1', 'KDR', 'PDGFRB', 'FGFR1', 'FGFR2'], 'selpercatinib': ['RET', 'FLT1', 'FLT4', 'FGFR1', 'FGFR2', 'FGFR3'], 'brigatinib': ['ALK', 'EGFR', 'ABL1', 'IGF1R', 'FLT3', 'INSR', 'MET', 'ERBB4', 'ERBB2'], 'amivantamab': ['EGFR', 'MET', 'FCGR3A'], 'ramucirumab': ['KDR'], 'osimertinib': ['EGFR'], 'necitumumab': ['EGFR']}
--

USE CASES:
Of the top 30 predicted genes, these ones are targets of approved drugs not in the training set: ['KDR', 'RET', 'FLT3', 'EGFR', 'PDGFRB']
The approved drugs (not in training) that have at least one of those genes as targets are: {'pralsetinib': ['RET', 'DDR1', 'NTRK3', 'FLT3', 'JAK1', 'JAK2', 'NTRK1', 'KDR', 'PDGFRB', 'FGFR1', 'FGFR2'], 'selpercatinib': ['RET', 'FLT1', 'FLT4', 'FGFR1', 'FGFR2', 'FGFR3'], 'brigatinib': ['ALK', 'EGFR', 'ABL1', 'IGF1R', 'FLT3', 'INSR', 'MET', 'ERBB4', 'ERBB2'], 'amivantamab': ['EGFR', 'MET', 'FCGR3A'], 'ramucirumab': ['KDR'], 'osimertinib': ['EGFR'], 'necitumumab': ['EGFR']}
--

USE CASES:
Of the top 50 predicted genes, these ones are targets of approved drugs not in the training set: ['KDR', 'RET', 'FLT3', 'EGFR', 'ERBB2', 'VEGFA', 'FLT1', 'ABL1', 'FGFR2', 'PDGFRB']
The approved drugs (not in training) that have at least one of those genes as targets are: {'pralsetinib': ['RET', 'DDR1', 'NTRK3', 'FLT3', 'JAK1', 'JAK2', 'NTRK1', 'KDR', 'PDGFRB', 'FGFR1', 'FGFR2'], 'selpercatinib': ['RET', 'FLT1', 'FLT4', 'FGFR1', 'FGFR2', 'FGFR3'], 'brigatinib': ['ALK', 'EGFR', 'ABL1', 'IGF1R', 'FLT3', 'INSR', 'MET', 'ERBB4', 'ERBB2'], 'bevacizumab': ['VEGFA', 'C1QA', 'C1QB', 'C1QC', 'FCGR3A', 'FCGR1A', 'FCGR2A', 'FCGR2B', 'FCGR2C'], 'amivantamab': ['EGFR', 'MET', 'FCGR3A'], 'ramucirumab': ['KDR'], 'osimertinib': ['EGFR'], 'necitumumab': ['EGFR']}
--

USE CASES:
Of the top 100 predicted genes, these ones are targets of approved drugs not in the training set: ['KDR', 'RET', 'FLT3', 'EGFR', 'ERBB2', 'VEGFA', 'IGF1R', 'FLT4', 'FLT1', 'ABL1', 'FGFR2', 'PDGFRB']
The approved drugs (not in training) that have at least one of those genes as targets are: {'pralsetinib': ['RET', 'DDR1', 'NTRK3', 'FLT3', 'JAK1', 'JAK2', 'NTRK1', 'KDR', 'PDGFRB', 'FGFR1', 'FGFR2'], 'selpercatinib': ['RET', 'FLT1', 'FLT4', 'FGFR1', 'FGFR2', 'FGFR3'], 'brigatinib': ['ALK', 'EGFR', 'ABL1', 'IGF1R', 'FLT3', 'INSR', 'MET', 'ERBB4', 'ERBB2'], 'bevacizumab': ['VEGFA', 'C1QA', 'C1QB', 'C1QC', 'FCGR3A', 'FCGR1A', 'FCGR2A', 'FCGR2B', 'FCGR2C'], 'amivantamab': ['EGFR', 'MET', 'FCGR3A'], 'ramucirumab': ['KDR'], 'osimertinib': ['EGFR'], 'necitumumab': ['EGFR']}
--
